How should I monitor lipid levels in patients on statin therapy, and what are the targets for treatment?

Guideline-aligned answer with reasoning, red flags and references. Clinically reviewed by Dr Kola Tytler MBBS CertHE MBA MRCGP.

Posted: 16 August 2025Updated: 16 August 2025 Guideline-Aligned (High Confidence) Clinically Reviewed
Dr Kola Tytler MBBS CertHE MBA MRCGPClinical Lead • iatroX

Monitor lipid levels by measuring a non-fasting full lipid profile 2–3 months after starting or changing lipid-lowering treatment ,.

If the lipid target is met, continue treatment if the shared decision is to do so; do not routinely de-escalate treatment unless clinically indicated or based on patient needs or preferences ,.

If the lipid target is not met, consider treatment optimization or escalation after an informed discussion with the patient about risks and benefits ,.

The treatment targets for secondary prevention of CVD are LDL cholesterol levels of 2.0 mmol/L or less, or non-HDL cholesterol levels of 2.6 mmol/L or less ,.

Further monitoring of liver transaminases should be done 2–3 months after starting or changing treatment, and again at 12 months, unless clinically indicated ,.

Related Knowledge Topics

Educational content only. Always verify information and use clinical judgement.